Aims
The first aim of this ERBP paper is to review the current literature on renal disease in Fabry patients, in order to provide guidance to the nephrologist on when to screen for this disease and why, and to understand the preferred methods that should be used for screening.
The second aim is to provide guidance on the follow-up, prevention and treatment of renal disease, and its complications (proteinuria, renal failure). The role of ERT, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and renal replacement therapy (RRT) is reviewed.
Flowchart
Flowchart for screening for fabry disease in Chronic Kidney Disease patients
© The Author. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Volume 28, Issue 3, March 2013, Pages 505–517, https://doi.org/10.1093/ndt/gfs526
Downloads
Guideline Development Group
Disclosure of Interest (DoI)
ERA Operative Headquarters
Strada dei Mercati 16/A
I-43126 Parma – Italy
Phone: +39 0521 989078
E-mail: secretariat@era-online.org
ERA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom